RENATA study—Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer—real-world use

BACKGROUND: In hormone receptor-positive, HER-2 negative (HR+/HER2−) advanced breast cancer (ABC) endocrine therapy (ET) plus cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in first and second line improved progression-free survival (PFS), overall response rate (ORR) and clinical benefit rate (CB)...

Descripción completa

Detalles Bibliográficos
Autores principales: Petracci, Fernando, Abuin, Gonzalo Gomez, Pini, Alejandra, Chacón, Matías
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302883/
https://www.ncbi.nlm.nih.gov/pubmed/32582373
http://dx.doi.org/10.3332/ecancer.2020.1058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302883/
https://www.ncbi.nlm.nih.gov/pubmed/32582373
http://dx.doi.org/10.3332/ecancer.2020.1058

Ejemplares similares